Kurma Partners’ Post

Neurovation Labs is pleased to announce its acceptance to the NewYorkBIO Fellows Program, an initiative that provides emerging biotech companies with extensive resources, networks, and opportunities to accelerate innovation and improve patient outcomes. CEO Jennifer Perusini, Ph.D. comments, "Acceptance into the NewYorkBIO Fellows Program provides us with a unique platform to significantly expand our visibility within the biotechnology ecosystem. As we advance our pipeline – including our lead programs for PTSD, brain trauma, and related conditions rooted in emotion dysregulation – access to this network will be instrumental in forging strategic partnerships, attracting investment, and accelerating our path toward bringing transformative solutions to patients.” Read the press release: https://bit.ly/4pJRqW6 #NewYorkBIO #Innovation #PrecisionMedicine #Neuroscience #PTSD #Biotech #bringingthefighttoPTSD

Aerska, a Dublin-based biotech company focused on transforming treatments for neurological diseases, has raised €17 million in Seed funding to advance systemically administered RNA interference (RNAi) therapies aimed at silencing genes that drive brain disorders. The round was co-led by age1, BACKED VC and Speedinvest, with participation from Blueyard, Lingotto (Exor), Norrsken VC, Kerna, PsyMed, and Ada Ventures. Jack O'Meara | Stuart Milstein | David Hardwicke 🔗 Read full article link in comment #Aerska #Biotech #RNAiTherapies #BrainDiseases #Neuroscience #GeneticMedicine #CNSResearch #PrecisionMedicine #funding #eustartups #news

We’re excited to announce the establishment of Epigeneer GmbH in Mainz, Germany, a new subsidiary of AdRegeneer AG. Epigeneer focuses on advancing transdermal regenerative therapies for patients with Multiple Sclerosis (MS) and other neurodegenerative diseases. This new step strengthens our European presence and brings us closer to our mission of helping patients regain movement, sensation, and independence. 🔗 Learn more: https://lnkd.in/ettaRJpC #biotech #neuroscience #MultipleSclerosis #regenerativetherapy #AdRegeneer #Epigeneer

Innovation in Alzheimer’s research starts with rethinking how we use data.   IGC Pharma’s AI-driven platform, AHA: Agentic Harmonization Assistant, has been recognized on the global stage—advancing to the semi-finals of the Alzheimer’s Insights AI Prize organized by the Alzheimer's Disease Data Initiative   By building on the foundation of MINT-AD, our deep-learning platform that unites complex clinical and biological information, we’re pushing the boundaries of what’s possible in Alzheimer’s drug discovery.   For more information, please visit: https://bit.ly/47D7n9C #AlzheimersResearch #AIinHealthcare #HealthcareInnovation #Neuroscience #IGCPharma

Exciting News: I’m Launching NeuroVivo LLC After 20+ years of hands-on experience in preclinical in vivo research, I’m thrilled to announce the launch of NeuroVivo—a consulting service dedicated to helping institutions strengthen their in vivo operations. NeuroVivo provides strategic, in-person support for study design, troubleshooting, team training, and regulatory readiness. Whether you're scaling a vivarium, navigating a challenging study, or wanting to optimize the outcome of a CRO-run program, I’m here to help you build clarity, confidence, and reproducibility into your workflows. I created NeuroVivo because reproducibility, rigor, and collaboration matter—and I believe good science starts with empowered teams and thoughtful execution. 👉 If your team is facing in vivo challenges, I’d love to connect. I’m currently offering free discovery calls to explore how NeuroVivo can support your goals. Feel free to reach out or share this with someone navigating in vivo research. #NeuroVivo #InVivoConsulting #PreclinicalResearch #Neuroscience #AAALAC #CROStrategy #ScientificIntegrity #ConsultingLaunch #CROLiaison #StudyIntegrity

On our last post, we talked about using primary DRG neurons to understand the full physiological system. So, how do you bridge the species gap to validate the human target? 🐁 ➡️ 👤 The answer is iPSC-derived sensory neurons.  This cutting-edge technology allows us to test a compound's effect on true human proteins, completely eliminating the species gap. It's the most direct way to get early, decisive validation of your compound's mechanism of action in a human-relevant model. By combining insights from both the system (DRGs) and the target (iPSCs), you create the most confident path to the clinical stage of your CNS and pain drug program. Learn more about our state- of-the-art cell platform https://bit.ly/4lKaYbd #iPSC #HumanRelevant #DrugDiscovery #Innovation #Neuroscience #Biotech #CRO

Alto Neuroscience announced today that it will accelerate the development of ALTO-207 for people with treatment-resistant depression (TRD), following a successful outcome from a recent meeting with the FDA.   The $50 million private placement announced earlier today supports expanded development of ALTO-207, and the Company expects to initiate a Phase 3 study by early 2027 following Phase 3 readiness work and alignment with the FDA on the planned study design.   Read more here: https://lnkd.in/gYJGjEZR #TRD #biotech #neuroscience

We have been trying to understand various aspects of Amyotrophic Lateral Sclerosis (ALS) for over a decade now. Our first paper, published in 2016 (Vats et al.), reported a novel SOD1 mutation in a family with ALS — the first genetic variation associated with ALS to be identified from India. Building on this, Abhishek and Sagar demonstrated the pathogenic nature of this mutation in a cellular model (Verma et al., FASEB 2024). We are now using these and other genetic models to screen small molecules (CSIR-Aspire, 2024) and develop RNA-based therapeutics (ICMR Intermediate Grant, 2024) for ALS. In this small piece of work, we have tried to identify candidate microRNAs that regulate key molecular pathways implicated in ALS. Anjali, Shiffali, and Sagar worked as a close-knit team — diligently reviewing literature,performing analyses, and validating the findings in patient samples. We have had the privilege of learning about this devastating disease from Dr. M. Gourie-Devi, one of the most distinguished neurologists of our nation and a guiding light for all our work in ALS 🙏. Above all, we express our deepest gratitude to our patients and their caregivers 💙 — your courage and resilience continue to inspire us. The sufferings are real, but so is our hope — to one day bring meaningful relief through our research.🤞

Exciting news for our Forbion portfolio company Kynexis. The company has dosed the first patient in their Phase 2 clinical trial of KYN-5356 for cognitive impairment associated with schizophrenia. The Phase 2 trial seeks to establish proof-of-concept of KYN-5356, a first-in-class small molecule that is potent and highly selective for KAT-II. Approximately 150 patients will be enrolled across the US and topline results are expected by Q4 2026.   To find out more about KYN-5356 and its potential for brain diseases, please click here: https://lnkd.in/ehpmjTR9 #VentureCapital #LifeSciences #Biotech #Kynexis #Schizophrenia #Neuroscience #ClinicalTrials Dr. Dmitrij Hristodorov Tim Lohoff, Ph.D. 

[No Profile Picture - Anonymous User] Anonymous Researcher Shared with the Scientific Community Disrupting Parkinson's: Unveiling the Project Genesis Protocol The fight against \alpha-synucleinopathies requires a multi-faceted approach. Our anonymous group is sharing a conceptual breakthrough—the Project Genesis Protocol—a unified molecular system (\text{SYN-CAP-DELIVERY-001}) designed to achieve three goals simultaneously: Cap. Target. Clear. The System's Core Mechanisms: * Capping: A precisely engineered 12-residue peptide (\text{T V G V S G K T P E V A}, or \text{SYN-CAP-001}) acts as a \beta-Sheet Breaker to halt the toxic aggregation and propagation of \alpha-synuclein seeds. * Targeting: The peptide is encapsulated within Dopamine-Conjugated Extracellular Vesicles (Dopa-EVs). This mechanism ensures efficient BBB transit and selective uptake by vulnerable dopaminergic neurons in the Substantia Nigra. * Clearance: The Dopa-EV vector inherently stimulates the Autophagy-Lysosomal Pathway (ALP). This synergy ensures the neuron is primed to rapidly clear the newly capped \alpha-syn complex. This integrated System Patch targets the cause of the disease by neutralizing the toxic protein and simultaneously empowering the cell to dispose of it. We believe this strategy represents a path to truly disease-modifying therapies for PD. We welcome feedback and collaborative discussion on the path to pre-clinical validation. #ParkinsonsDisease #Neuroscience #DrugDiscovery #AlphaSynuclein #EVs #Autophagy #Biotech #ConceptualResearch (Estimated Character Count: ~1,200 characters including hashtags, well under the 3,000 limit.)